Alnylam Pharmaceuticals (ALNY) Earning Somewhat Positive Media Coverage, Accern Reports

News stories about Alnylam Pharmaceuticals (NASDAQ:ALNY) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Alnylam Pharmaceuticals earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.0844304701276 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:

Alnylam Pharmaceuticals (NASDAQ ALNY) traded down $4.23 during trading on Friday, reaching $127.73. 718,741 shares of the company traded hands, compared to its average volume of 1,090,000. Alnylam Pharmaceuticals has a 52-week low of $35.98 and a 52-week high of $147.63. The firm has a market capitalization of $12,560.00, a PE ratio of -24.33 and a beta of 2.98. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.23) by ($0.11). Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. During the same quarter in the previous year, the business posted ($1.21) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 24.8% on a year-over-year basis. research analysts anticipate that Alnylam Pharmaceuticals will post -5.21 earnings per share for the current fiscal year.

ALNY has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $85.00 price objective (down from $98.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Goldman Sachs Group upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “conviction-buy” rating in a research report on Friday, December 15th. Instinet initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Friday, September 15th. They issued a “reduce” rating and a $56.00 target price for the company. Piper Jaffray Companies reiterated an “overweight” rating and issued a $110.00 target price (down from $126.00) on shares of Alnylam Pharmaceuticals in a research report on Thursday, September 7th. Finally, Leerink Swann reiterated a “market perform” rating and issued a $72.00 target price (down from $83.00) on shares of Alnylam Pharmaceuticals in a research report on Friday, September 8th. They noted that the move was a valuation call. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. Alnylam Pharmaceuticals currently has an average rating of “Buy” and an average price target of $121.85.

In related news, CEO John Maraganore sold 74,000 shares of the firm’s stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $126.86, for a total transaction of $9,387,640.00. Following the completion of the sale, the chief executive officer now directly owns 223,710 shares in the company, valued at $28,379,850.60. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Akshay Vaishnaw sold 33,666 shares of the firm’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $121.46, for a total transaction of $4,089,072.36. Following the sale, the executive vice president now owns 45,201 shares of the company’s stock, valued at $5,490,113.46. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 237,330 shares of company stock valued at $30,520,815. 4.30% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Alnylam Pharmaceuticals (ALNY) Earning Somewhat Positive Media Coverage, Accern Reports” was published by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://transcriptdaily.com/2018/01/06/alnylam-pharmaceuticals-alny-earning-somewhat-positive-media-coverage-accern-reports.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply